Original reporting and analysis on the stories shaping biotech.
Regeneron, the antibody powerhouse, just made a surprise $2.1 billion bet on radioactive cancer drugs through a deal with Telix Pharmaceuticals. It's the latest sign that radiopharmaceuticals have gone from niche curiosity to the hottest arms race in oncology.
The FDA just fast-tracked a new guided-missile cancer drug for small cell lung cancer, one of oncology's most brutal diseases. With a 48% response rate where standard options barely move the needle, Daiichi Sankyo and Merck's $4 billion bet might be about to pay off.
Allogene's off-the-shelf CAR-T therapy cleared residual lymphoma cells at 3.5 times the rate of observation alone, with zero serious side effects. If durability data holds, the $10K-per-dose treatment could upend the $400K autologous CAR-T model entirely.
IDEAYA Biosciences just dropped uveal melanoma trial data that more than doubled progression-free survival in patients who had almost no treatment options. Wall Street loved it, an FDA filing is coming, and a half-billion-dollar partnership is fueling what comes next.
Seaport Therapeutics and Hemab Therapeutics both filed $100 million IPOs on the exact same day, targeting depression and rare bleeding disorders respectively. Their simultaneous filings say a lot about where the biotech IPO market stands in Q2 2026.
For 40 years, the RAS protein was cancer research's most infamous failure: too smooth, too stubborn, too "undruggable." Revolution Medicines just posted Phase 3 results that nearly doubled survival in pancreatic cancer patients, and the implications go far beyond one drug.
Gilead Sciences just closed its third acquisition in six weeks, bringing its recent M&A tab to nearly $13 billion. The latest buy: a German ADC biotech that could reshape how cancer drugs find their targets.
Western pharma companies poured $52 billion into Chinese biotech licensing deals in just the first two months of 2026, nearly matching all of 2024 in eight weeks. The shopping spree signals something bigger than bargain hunting: a fundamental power shift in where the world's best drugs are being invented.
Avalyn Pharma wants to take two blockbuster lung disease drugs and reinvent how patients receive them. The company just filed for a $100 million IPO, betting that inhaling these medications beats swallowing them.
A Shanghai biotech just raised $110 million to chase something nobody has achieved: the first CAR-T cell therapy approved for solid tumors. Oricell's early liver cancer data is turning heads, and the IPO clock is ticking.
The FDA rejected Replimune's melanoma gene therapy RP1 for the second time, citing the same trial design flaws it flagged five years ago. The decision sends a chilling message to every company betting on oncolytic virus therapies with single-arm studies.
The FDA just approved Eli Lilly's Foundayo, an oral GLP-1 pill for obesity that you can pop any time of day without fasting or needles. With two-thirds of injectable patients quitting within a year, this little tablet could blow the market wide open.
Neurocrine Biosciences is spending $2.9 billion to acquire the only approved drug for a rare hunger disorder most people have never heard of. The deal says a lot about where biotech's biggest bets are heading.
Biotech IPOs raised $1.7 billion in Q1 2026, the biggest quarter since 2021, with median deal sizes more than doubling. But the real story isn't just the money coming back; it's about which companies are getting funded and what Eli Lilly's aggressive shopping spree tells us about what's next.
The FDA rejected Replimune's melanoma drug RP1 for the second time, despite strong response rates and breakthrough therapy designation. The decision sends a clear signal: single-arm oncology trials may no longer cut it for approval.
A veteran cell therapy CEO just jumped ship to lead a radioactive cancer therapy company. Frédéric Desdouits' move from TreeFrog Therapeutics to Orano Med is the latest sign that targeted alpha therapy is pulling the biotech industry's best talent into its orbit.
A 21-mile-wide waterway between Iran and Oman is nearly shut down, and it's quietly threatening the global drug supply. No shortages yet, but the clock on pharma's inventory buffers is ticking.
Almost every RNA drug on the market goes to the liver. Vivatides Therapeutics just raised $54 million to deliver RNA everywhere else, tackling one of biotech's hardest unsolved problems.
Biotech IPOs raised a record $1.7 billion in Q1 2026, but only a select few made it through the door. The public market has become an exclusive club where late-stage data and billion-dollar backing are the price of admission.
Eli Lilly and Biogen dropped nearly $14 billion in acquisitions on the same day, sending the biotech index soaring 7%. It might be just the beginning of a record-breaking M&A year.
Eli Lilly just got FDA approval for Foundayo, the first small-molecule obesity pill that you can take anytime, anywhere, no needles required. With $1.7 billion in projected first-year sales and a price that undercuts injectables by 85%, the GLP-1 wars just went oral.
A small biotech developing a promising liver disease treatment was killed not by bad science or a failed trial, but by a single FDA meeting cancellation. Kezar Life Sciences' collapse reveals how regulatory delays are becoming an existential threat to the companies driving biomedical innovation.
Join thousands of biotech professionals who start their day with our free, daily briefing.